Abstract
AbstractMalignant pleural mesothelioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% five-year survival for early disease. Drug-induced mitochondrial priming measured by dynamic BH3 profiling identifies efficacious drugs in multiple disease settings. We use high throughput dynamic BH3 profiling (HTDBP) to identify drug combinations that prime primary MPM cells derived from patient tumors, which also prime patient derived xenograft (PDX) models. A navitoclax (BCL-xL/BCL-2/BCL-w antagonist) and AZD8055 (mTORC1/2 inhibitor) combination demonstrates efficacy in vivo in an MPM PDX model, validating HTDBP as an approach to identify efficacious drug combinations. Mechanistic investigation reveals AZD8055 treatment decreases MCL-1 protein levels, increases BIM protein levels, and increases MPM mitochondrial dependence on BCL-xL, which is exploited by navitoclax. Navitoclax treatment increases dependency on MCL-1 and increases BIM protein levels. These findings demonstrate that HTDBP can be used as a functional precision medicine tool to rationally construct combination drug regimens in MPM and other cancers.
Funder
U.S. Department of Health & Human Services | National Institutes of Health
Ludwig Institute for Cancer Research
U.S. Department of Defense
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference52 articles.
1. Landau, D. A. Mesothelioma. Asbestos.com. Retrieved May 17, 2023, from https://www.asbestos.com/mesothelioma/ (2023).
2. Sterman, D. H., Litzky, L. A. & Kaiser, L. R. Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma. In UpToDate (ed Post, T. W.) (UpToDate, Waltham, MA, accessed 23 September 2021).
3. Rusch, V. W. et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J. Thorac. Oncol. 7, 1631–1639 (2012).
4. Musk, A. W. et al. Predicting survival in malignant mesothelioma. Eur. Respir. J. 38, 1420–1424 (2011).
5. Yang, C. F. et al. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 49, 1607–1613 (2016).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献